Inside the Structural Reforms That Made IU Indianapolis a Translational Overachiever
How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.
Beth Israel Deaconess Medical Center
14Institution Overview
#14In Institutes & Centers
#22In Research Capabilities
#18In Entrepreneurial Readiness
#15In Market Translation
Index 20 Institutes & Centers
Boston, MA
Beth Israel Deaconess Medical Center ranks 14th among biomedical institutes in the Cure Innovation Index and is based in Boston, Massachusetts. Its profile tilts toward market translation, where it places in the upper tier, supported by a Clinical and Translational Science Award, faculty-led clinical trials, and an incubator with an entrepreneur-in-residence program. Research capabilities and entrepreneurial readiness are above average across the field. As a medical center embedded in Boston's biomedical corridor, Beth Israel Deaconess reflects strength concentrated in the translation-facing dimensions of the index.
Ranking Metrics
Research Capabilities
Beth Israel Deaconess Medical Center ranked below average for Research Capabilities, a measure of the foundational infrastructure and resources that enable an institution to conduct high-quality, innovative science. Out of the factors in this category, Beth Israel Deaconess Medical Center fared best in Funding Support.
Learn MoreEntrepreneurial Readiness
Beth Israel Deaconess Medical Center ranked below average for Entrepreneurial Readiness, a measure of whether the institution has built a supportive ecosystem for entrepreneurship and whether faculty are engaged in and incentivized toward commercial activity. Out of the factors in this category, Beth Israel Deaconess Medical Center fared best in Faculty Engagement.
Learn MoreMarket Translation
Beth Israel Deaconess Medical Center ranked above average for Market Translation, a measure of how effectively a research institution moves scientific discovery out of the lab and into real-world clinical and commercial applications. Out of the factors in this category, Beth Israel Deaconess Medical Center fared best in Health Impact.
Learn More
Cure Innovation Index Methodology
From a pool of more than 6,000 institutions, the top 303 were ranked using two dozen indicators — from scientific foundation and lab infrastructure to patents, products, and partnerships — drawn from more than a dozen federal and commercial databases, an original audit of all institutions, and surveys of more than 3,300+ scientists, industry leaders, and biomedical experts.
Insights From the Cure Innovation Index
Explore by Category
Innovation isn't a single moment — it's an entire ecosystem. The Index evaluates institutions across two dozen indicators, grouped in three core domains that reveal the full picture of what it takes to turn groundbreaking science into real-world impact.
New York State Has Built One of the Country’s Most Powerful Biomedical Ecosystems
With 27 institutions ranked among the country’s top biomedical innovators, New York’s research cluster spans the entire state, and outperforms nearly every other in the country.
Universities Face an Uncertain Future as Gap To Industry Keeps Growing
As NIH funding shrinks and industry pulls back from early-stage science, universities are rethinking how discoveries move from the lab to the market.
How Universities Became the Engine of the Biotech Industry
The Bayh-Dole Act turned federally funded research into a commercialization pipeline that built American biotech. Forty-five years later, that pipeline faces a new set of political and financial pressures that could reshape how it works.